FDA 483 - Dendreon Pharmaceuticals LLC - November 08, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Dendreon Pharmaceuticals, LLC in Seal Beach, CA, a biologic drug manufacturer, revealed significant deficiencies across multiple areas. The firm was cited for issues including inadequate batch production records, untimely investigations into sterility failures, and a lack of proper procedures for aseptic processing and environmental monitoring. Additional concerns involved insufficient data verification, improper material handling and storage, and inadequate temperature control and equipment maintenance.
ID · 00e3c702-5196-4c88-8791-bb84ac9d5006